Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance

BMJ. 2021 Oct 1:375:n2195. doi: 10.1136/bmj.n2195.

Authors

Sue Pavord¹, Beverley J Hunt², Daniel Horner^{3

4}, Susan Bewley⁵, Justine Karpusheff⁶; Guideline Committee

Affiliations

¹ Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Thrombosis & Haemophilia Centre, Guy's & St Thomas NHS Foundation Trust & King's College London, UK.
³ Critical Care Unit, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UK.
⁴ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, UK.
⁵ Department of Women and Children's Health, King's College London, UK.
⁶ National Institute for Health and Care Excellence (NICE), London, UK Justine.Karpusheff@nice.org.uk.

PMID: 34598931
DOI: 10.1136/bmj.n2195

No abstract available

Publication types

Practice Guideline

MeSH terms

COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 Vaccines / adverse effects*
Factor Xa Inhibitors / therapeutic use*
Humans
Immunoglobulins, Intravenous / therapeutic use*
Pandemics
Purpura, Thrombocytopenic, Idiopathic / chemically induced
Purpura, Thrombocytopenic, Idiopathic / diagnosis
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
SARS-CoV-2
Thrombosis / chemically induced
Thrombosis / diagnosis
Thrombosis / drug therapy*
United Kingdom / epidemiology
Vaccination

Substances

COVID-19 Vaccines
Factor Xa Inhibitors
Immunoglobulins, Intravenous